A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Leukemia

• Publication date

  2007-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.leu.2404816PMID 17581608
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

  2007cited by this paper
• A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.

  2007cited by this paper
• Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

  2007cited by this paper
• Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions

  2007cited by this paper
• A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

  2007cited by this paper
• International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

  2006cited by this paper
• A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

  2006cited by this paper
• Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

  2006cited by this paper
• Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosiswith myeloid metaplasia at the Mayo Clinic

  2006cited by this paper
• Prognosis in transplant‐eligible patients with agnogenic myeloid metaplasia

  2006cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.

  2005cited by this paper
• The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005cited by this paper
• The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

  2005cited by this paper
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  2005cited by this paper
• Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.

  2004cited by this paper
• In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia

  2003cited by this paper
• Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.

  2003cited by this paper
• Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.

  2002cited by this paper
• Blocking oncogenic Ras signaling for cancer therapy.

  2001cited by this paper
• Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

  2001cited by this paper
• Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

  2001cited by this paper
• Current status of clinical trials of farnesyltransferase inhibitors

  2001cited by this paper
• Myelofibrosis with myeloid metaplasia.

  2000cited by this paper
• Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia.

  2000cited by this paper
• RAS and leukemia: from basic mechanisms to gene-directed therapy.

  1999cited by this paper
• Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia

  1999cited by this paper
• Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

  1999cited by this paper
• Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study.

  1999cited by this paper
• The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.

  1997cited by this paper
• Traitement par hydroxyurée d'une polyglobulie primitive chez un enfant de 11 ans

  1996cited by this paper
• [Treatment with hydroxyurea of polycythemia vera in a 11 year-old child].

  1996cited by this paper
• BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.

  1993cited by this paper
• Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque.

  1974cited by this paper

• Research trends in essential thrombocythemia from 2001 to 2024: a bibliometric analysis

  2025cites this paper
• Emerging treatments for classical myeloproliferative neoplasms.

  2017cites this paper
• Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.

  2015cites this paper
• Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

  2015cites this paper
• Orphan drugs for myelofibrosis

  2014cites this paper
• Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

  2013cites this paper
• Novel therapies in the classical BCR–ABL-negative myeloproliferative neoplasms

  2013cites this paper
• Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

  2012cites this paper
• Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

  2011cites this paper
• Therapeutic approaches in myelofibrosis

  2011cites this paper
• Conventional and Investigational Therapy for Primary Myelofibrosis

  2011cites this paper
• A phase 1‐2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndrome

  2011cites this paper
• Blastic Transformation of Classic Myeloproliferative Neoplasms

  2011cites this paper
• Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

  2011cites this paper
• Deactylase inhibition in myeloproliferative neoplasms

  2010cites this paper
• Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Myelofibrosid (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)]

  2010cites this paper
• Therapy of myelofibrosis (excluding JAK2 inhibitors)

  2010cites this paper
• JAK2 gene mutation: impact on pathogenesis, classification, and management of myeloproliferative neoplasms

  2010cites this paper
• Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms

  2010cites this paper
• 5-Azacitidine has limited therapeutic activity in myelofibrosis

  2009cites this paper
• Pharmacotherapy of Hematologic Malignancies with Tipifarnib

  2009cites this paper
• Treatment options for essential thrombocythemia and polycythemia vera

  2009cites this paper
• Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

  2009cites this paper
• Novel strategies for patients with chronic myeloproliferative disorders

  2009cites this paper
• Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

  2009cites this paper
• CELL CYCLE PHARMACOLOGY, ANTIPROLIFERATION, AND APOPTOSIS

  2009cites this paper
• Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia : a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib ( R 115777 , Zarnestra ) combined with etoposide

  2009cites this paper
• Conventional and New Treatment Modalities in Myelofibrosis and the Current Role of Transplantation

  2008cites this paper
• New insights into the pathogenesis and treatment of chronic myeloproliferative disorders

  2008cites this paper
• Phase II Trialof Tipifarnib asMaintenanceTherapy in First Complete Remission inAdultswithAcuteMyelogenous Leukemia andPoor-Risk Features

  2008cites this paper
• From palliation to epigenetic therapy in myelofibrosis.

  2008cites this paper
• Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia

  2008cites this paper
• Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

  2008cites this paper
• Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features

  2008cites this paper
• Choosing between stem cell therapy and drugs in myelofibrosis

  2008cites this paper
• Antiangiogenic therapy in myelodysplastic syndromes: Is there a role?

  2008cites this paper
• Ceramide signaling in cancer and stem cells.

  2008cites this paper
• Acute Leukemia Arising from the Myeloproliferative Disorders: Challenge and Opportunity

  2008cites this paper
• Chronic idiopathic myelofibrosis

  2008cites this paper
• Clinical Trials and Observations

  2008cites this paper
• From the Guest Editors

  2007cites this paper
• New and Old Treatment Modalities in Primary Myelofibrosis

  2007cites this paper
• Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

  2006cites this paper